Intelligence · Patent portfolio
Regeneron Ireland Designated Patents
Full USPTO pharma patent portfolio for Regeneron Ireland Designated — grant dates, expiration, and drug cross-links.
- Patents
- 8,292
- Expiring ≤24m
- 426
Quick answer
Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months — use filters for patent-cliff planning.
-
US 8114390
Method for treating hair growth disorders, such as female pattern alopecia, and compositions useful therefore
granted -
US 8114843
Photoreactive regulator of protein function and methods of use thereof
granted -
US 8114590
Diagnosis and treatment of chronic lymphocytic leukemia (CLL)
granted -
US 8114648
In vivo incorporation of unnatural amino acids
granted -
US 8114446
Methods for modulating eicosanoid metabolism
granted -
US 8109894
Indwelling heat exchange catheter and method of using same
granted -
US 8110569
Enantiomerically pure S-etifoxine, pharmaceutical compositions thereof and methods of their use
granted -
US 8110554
Peptides whose uptake by cells is controllable
granted -
US 8110594
Diarylthiohydantoin compounds
granted -
US 8106017
Peptides for promoting hair growth and improving wrinkle and cosmetic compositions comprising the same
granted -
US 8105262
Indwelling heat exchange catheter and method of using same
granted -
US 8105263
Indwelling heat exchange catheter and method of using same
granted -
US 8105264
Indwelling heat exchange catheter and method of using same
granted -
US 8105607
Porin B (PorB) as a therapeutic target for prevention and treatment of infection by Chlamydia
granted -
US 8108030
Method and apparatus to identify vulnerable plaques with thermal wave imaging of heated nanoparticles
granted -
US 8101572
Methods for promoting wound healing and/or reducing scar formation
granted -
US 8101370
Genes from the 20q13 amplicon and their uses
granted -
US 8101174
Pharmaceutical compositions for treating arthritis and inflammatory disease
granted -
US 8101740
Positron emission tomography probes for imaging immune activation and selected cancers
granted -
US 8101158
Methods for treating cerebrovascular disease comprising administering an agent that inhibits prokineticin receptor activity
granted -
US 8101159
In vivo methods of identifying compounds which target suppressed cancer cells
granted -
US 8101198
Osteogenic enhancer composition
granted -
US 8101745
Lung-targeted drugs
granted -
US 8101382
Modified vitamin K-dependent polypeptides
granted -
US 8097612
Compositions and methods relating to novel compounds and targets thereof
granted -
US 8097455
System and method for forming skeletal muscle constructs having functional tissue interfaces
granted -
US 8097701
Aldehyde tags, uses thereof in site-specific protein modification
granted -
US 8093214
Method of treating or preventing tissue deterioration, injury or damage due to congestive heart failure
granted -
US 8093286
Methods for treatment with bucindolol based on genetic targeting
granted -
US 8092812
Methods and compositions for immunization against chlamydial infection and disease
granted -
US 8092838
Use of hydrogen sulfide in the treatment of eye diseases
granted -
US 8093274
Inhibitors of protein prenyltransferases
granted -
US 8088749
Compositions and methods for treating cancer
granted -
US 8088894
Methods and compositions for Mycoplasma pneumoniae exotoxins
granted -
US 8088604
Production of defined monodisperse heparosan polymers and unnatural polymers with polysaccharide synthases
granted -
US 8088759
1,4-benzodiazepine-2,5-diones with therapeutic properties
granted -
US 8088931
Small molecule inhibitors of MDM2 and the uses thereof
granted -
US 8088908
Humanized anti-prostate stem cell antigen monoclonal antibody
granted -
US 8084248
Reverse genetic system for rift valley fever virus and uses thereof
granted -
US 8084016
Measurement of biosynthesis and breakdown rates of biological molecules that are inaccessible or not easily accessible to direct sampling, non-invasively, by label incorporation into metabolic derivatives and catabolitic products
granted -
US 8080527
Methods and compositions for prevention and treatment of inflammatory disease, autoimmune disease, and transplant rejection
granted -
US 8080256
Endophytic fungi from Pteromischum sp. plant, compounds and methods of use
granted -
US 8080523
Analogs of ShK toxin and their uses in selective inhibition of Kv1.3 potassium channels
granted -
US 8080578
Methods for treatment with bucindolol based on genetic targeting
granted -
US 8080579
Compositions and methods for treatment of inflammatory bowel disease
granted -
US 8075920
Administration of cells and cellular extracts for rejuvenation
granted -
US 8076470
VMP-like sequences of pathogenic Borrelia species and strains
granted -
US 8076294
Collagen-related peptides and uses thereof
granted
Frequently asked questions
How many patents does Regeneron Ireland Designated have?
8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Regeneron Ireland Designated patents expire?
426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources · Patent directory